Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%, Timolol 0.05% eye drops; Drug
Lead sponsor: Tavo Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Lynchburg, Virginia

Conditions: Glaucoma, Open-Angle
Interventions: Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT); Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 20 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, Standard of Care; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 66
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions: Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®); Drug
Lead sponsor: YS Life Science Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: SPARC0912, Reference0912; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-12286 0.5% Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open Angle
Interventions: brimonidine, timolol; Drug
Lead sponsor: Chicago Center for Vision Research; Other
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Open Angle Glaucoma
Interventions: Hydrus Microstent; Device
Lead sponsor: InSight Vision Center Medical Group, Inc; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fresno, California

Conditions: Primary Open-angle Glaucoma
Interventions: iStent inject, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 32
States / cities: Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: RKI983A, Latanoprost; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 29
States / cities: Artesia, California • Inglewood, California • La Jolla, California + 25 more

Conditions: Open-angle Glaucoma
Interventions: ANX007; Biological
Lead sponsor: Annexon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Primary Open Angle Glaucoma
Interventions: Xen, Aqueous shunt; Device
Lead sponsor: Price Vision Group; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions: Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Xen Gel Stent; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Pseudo-Exfoliative Glaucoma, Pigment Dispersion Glaucoma
Interventions: Selective laser trabeculoplasty; Procedure
Lead sponsor: Glaucoma Research & Education Group; Other
Eligibility: 0 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Pilocarpine, Ofloxacin, Prednisolone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine Tartrate Ophthalmic Solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 2 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: VISIOR video goggles; Device
Lead sponsor: Visior Technologies Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.

Evaluating Home Testing Devices for the Management of Glaucoma

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

24-hour Efficacy of AR-12286

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Hydrus Microstent as a Quality of Life Consideration

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

DE-117 Spectrum 5 Study

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Effect of Xen Implantation on the Aqueous Humor Proteome

Travoprost Five Day Posology Study

Retrospective Review of Xen Gel Stent Implantation With Open vs. Closed Conjunctiva Approach

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

The Efficacy of Selective Laser Trabeculoplasty

Pilocarpine After Combined Cataract/Trabectome Surgery

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

The Effects of Visior on Ocular Hemodynamics